MAXILUS
A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)
Arms / Cohorts
Experimental, Cohort 1:Erythropoiesis-stimulating Agents (ESA) Naïve
Accepting patients
Experimental, Cohort 2:Erythropoiesis-stimulating Agents (ESA) Relapsed or Refractory
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.